Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone refractory disease

C Mahler1, L J Denis

  • 1Department of Endocrinology, A.Z. Middleheim, Antwerp, Belgium.

Seminars in Surgical Oncology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Hormone refractory prostate cancer affects less than 20% of advanced cases. Early detection via prostate-specific antigen (PSA) monitoring aids in guiding second-line treatments for better survival outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, feasibility, and technical success of percutaneous cryoablation to treat vascular anomalies of the extremities.

Clinical radiology·2025
Same author

Paediatric sclerotherapy of vascular anomalies of the hand and digits.

Clinical radiology·2025
Same author

The effect of buzzy®, DistrACTION® cards on reducing pediatric pain and fear during blood collection in the rheumatology polyclinic: A randomized controlled trial.

Journal of pediatric nursing·2023
Same author

Opening up a tailored tutor qualification program for medical students to other healthcare students - a mixed-method study.

BMC medical education·2022
Same author

Failure of total hypophysectomy to remove intrasellar microadenoma in cushing's disease.

Endocrine pathology·2020
Same author

Attitudes towards interprofessional collaboration in young healthcare professionals.

Journal of interprofessional care·2019
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

Area of Science:

  • Oncology
  • Urology

Background:

  • Hormone-refractory prostate cancer (HRPC) develops in a minority of advanced cases, typically after 18 months of endocrine therapy.
  • HRPC is attributed to the emergence of hormone-independent or resistant prostate cancer cell lines.
  • Current second-line management lacks standardized criteria, hindering treatment comparisons.

Purpose of the Study:

  • To review the rationale behind current second-line therapeutic options for relapsed prostate cancer.
  • To highlight the importance of standardized criteria for evaluating treatment efficacy in HRPC.

Main Methods:

  • Review of current literature on second-line treatments for advanced prostate cancer.
  • Discussion on the role of prostate-specific antigen (PSA) monitoring in disease progression detection.

Related Experiment Videos

Main Results:

  • Prostate-specific antigen (PSA) monitoring is the primary tool for documenting disease progression.
  • Early PSA-based diagnosis in asymptomatic patients may improve treatment opportunities and drug evaluation.
  • Length of survival remains the most objective criterion, necessitating a clear definition of treatment failure.

Conclusions:

  • Standardized criteria for evaluating second-line therapies in HRPC are crucial.
  • Early detection of disease progression using PSA monitoring can optimize patient selection for novel therapies.
  • Further research is needed to establish universally accepted treatment guidelines for relapsed prostate cancer.